We are live on ! Find out more
AXSM icon

Axsome Therapeutics
AXSM

244 hedge funds and large institutions have $3.12B invested in Axsome Therapeutics in 2023 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 70 increasing their positions, 88 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% more call options, than puts

Call options by funds: $79.2M | Put options by funds: $41.4M

83% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 24

30% more funds holding in top 10

Funds holding in top 10: 10 → 13 (+3)

18% more capital invested

Capital invested by funds: $2.65B → $3.12B (+$473M)

8% more funds holding

Funds holding: 226 → 244 (+18)

2.6% more ownership

Funds ownership: 80.28% → 82.88% (+2.6%)

20% less repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 88

Holders
244
Holders Change
+18
Holders Change %
+7.96%
% of All Funds
3.56%
Holding in Top 10
13
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+30%
% of All Funds
0.19%
New
44
Increased
70
Reduced
88
Closed
24
Calls
$79.2M
Puts
$41.4M
Net Calls
+$37.9M
Net Calls Change
+$18.3M

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$62.9M
2
PA
Perceptive Advisors
New York
+$37.2M
3
Millennium Management
Millennium Management
New York
+$27.2M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$20.4M
5
BlackRock
BlackRock
New York
+$20.4M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$65.3M
2
NIP
Nicholas Investment Partners
California
-$20.9M
3
SCM
Soleus Capital Management
Connecticut
-$16.6M
4
Citadel Advisors
Citadel Advisors
Florida
-$13.8M
5
BI
BVF Inc
California
-$10M
Name Holding Trade Value Shares
Change 		Change in
Stake
VEA
176
Virtus ETF Advisers
New York
$354K +$46.1K +690 +18%
SSB
177
Sandy Spring Bank
Maryland
$348K – – –
FCM
178
Farallon Capital Management
California
$318K -$8.13M -121,653 -97%
AWM
179
Aries Wealth Management
Maine
$318K – – –
MCP
180
Mirador Capital Partners
California
$318K – – –
AIM
181
Aigen Investment Management
New York
$308K +$258K +3,866 New
JMFC
182
J.M. Forbes & Co
Massachusetts
$306K – – –
DC
183
Davenport & Co
Virginia
$304K +$255K +3,817 New
ONSWM
184
Old North State Wealth Management
North Carolina
$298K – – –
Public Employees Retirement Association of Colorado
185
Public Employees Retirement Association of Colorado
Colorado
$297K – – –
AC
186
AXQ Capital
New Jersey
$294K +$247K +3,700 New
AIP
187
Ameritas Investment Partners
Nebraska
$294K +$10.9K +163 +5%
Pathstone Holdings
188
Pathstone Holdings
New Jersey
$290K +$244K +3,649 New
Franklin Resources
189
Franklin Resources
California
$282K +$735 +11 +0.3%
BCI
190
Brinker Capital Investments
Pennsylvania
$260K -$29.4K -440 -13%
OPS
191
Orion Portfolio Solutions
Nebraska
$260K -$29.4K -440 -13%
Canada Life
192
Canada Life
Manitoba, Canada
$246K – – –
SEIA
193
Signature Estate & Investment Advisors
California
$242K – – –
IB
194
Intrust Bank
Kansas
$227K -$23.4K -350 -11%
Mariner
195
Mariner
Kansas
$217K +$182K +2,729 New
Prudential Financial
196
Prudential Financial
New Jersey
$217K +$182K +2,725 New
Squarepoint
197
Squarepoint
New York
$203K -$6.3M -94,211 -97%
LSA
198
Leonteq Securities AG
Switzerland
$187K +$20.1K +300 +15%
SG Americas Securities
199
SG Americas Securities
New York
$170K +$143K +2,141 New
TIM
200
Tortoise Investment Management
New York
$170K – – –
6 7
8
9 10

AXSM Hedge Fund Activity: Q4 2023 in Review

244 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q4 2023, worth a combined $3.12B — up 18% from $2.65B a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new AXSM positions and 24 closed out — a net gain of 20 holders — while 70 added to existing stakes and 88 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $62.9M. The largest seller was Fidelity Investments, cutting an estimated $65.3M.

  • 244 institutional investors held Axsome Therapeutics (AXSM) as of Q4 2023, up from 226 in Q3 2023.
  • Funds reported $3.12B of Axsome Therapeutics stock for Q4 2023, up 18% quarter-over-quarter.
  • 44 funds opened new Axsome Therapeutics positions in Q4 2023 and 24 closed out, a net change of +20 holders.
  • The largest Axsome Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $62.9M added.
  • The largest Axsome Therapeutics seller in Q4 2023 was Fidelity Investments, an estimated $65.3M sold.

Based on aggregated 13F filings for Q4 2023.